AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02434705 — intervention group
Intervention type: OTHER
Intervention: Antigen (wheat base soy sauce) spray
Description: Patients having a clinically indicated endoscopy for Eosinphilic Esophagitis will have two biopsies from the esophageal body, 10 cm above the gastroesophageal junction. After biopsies are taken, approximately 10 cc of wheat based soy sauce will be sprayed though an endoscopic catheter onto the esophageal mucosa. The endoscopic examination will be completed and Two additional endoscopic biopsies will be taken 10 cm above the gastroesophageal junction.
Study NCT01297595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: crizotinib
Description: Each subject will receive 250 mg single oral doses of oral liquid formulation and formulated capsule of crizotinib separated by at least 14 days.
Study NCT03637075 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intranasal insulin
Description: intranasal administration of insulin (160 IU)
Study NCT03637075 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo intranasal administration
Study NCT01855399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Coaching
Description: All participants will be assigned to a peer coach, who is a Detroit VA diabetes patient who previously had poor glycemic control but is currently in good control. Participants will receive information on their lab and blood pressure values and will be scheduled for an initial visit with their coach. The coach will then help them list questions and concerns they wish to discuss with their health care provider, practice raising their questions and concerns, and develop an action plan to address barriers to self-management they have identified. During the next six months, coaches will call their assigned peers once a week to provide support for their action steps.
Study NCT01855399 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Peer Coaching
Description: All participants will be assigned to a peer coach, who is a Detroit VA diabetes patient who previously had poor glycemic control but is currently in good control. Participants will receive information on their lab and blood pressure values and will be scheduled for an initial visit with their coach. The coach will then help them list questions and concerns they wish to discuss with their health care provider, practice raising their questions and concerns, and develop an action plan to address barriers to self-management they have identified. During the next six months, coaches will call their assigned peers once a week to provide support for their action steps.
Study NCT01855399 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision Aid
Description: The iDecide tool is designed to present key tailored, evidence-based information on diabetes and diabetes treatments. Importantly for a peer support intervention, all content information will be provided through the tool, with the role of the peer mentor being to assist the participant to go through the program and participate in helping the patient formulate questions and concerns to discuss with their health care provider, to set their own behavioral goals and action steps, and to help the participant practice raising the issues they plan to discuss with their health care provider.
Study NCT03233295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D3 B.O.N. Injection
Description: cholecalciferol 200,000IU
Study NCT03990805 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JOINTSTEM
Description: JOINTSTEM Autologous Adipose Tissue derived MSCs 1x10\^8cells/(saline), 1 time injection
Study NCT03990805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: saline, 1 time injection
Study NCT04033094 — intervention group
Intervention type: DRUG
Intervention: MorphaBond ER
Description: This was a retrospective, non-interventional study. Previous users of branded and generic products (tablets or capsules) with ER and immediate release (IR) release type formulations of oxycodone, oxymorphone, hydromorphone and morphine (except MorphaBond).
Study NCT04033094 — intervention group
Intervention type: DRUG
Intervention: Comparator Drug
Description: This was a retrospective, non-interventional study. Previous users of the MorphaBond ER brand of ER morphine sulfate with A-D labeling, by prescription or non-prescription.
Study NCT04397965 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cascade Continuous Glucose Monitor
Description: Continuous Glucose Monitoring
Study NCT02072525 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Menveo®
Description: One dose administered intramuscularly (IM) in the upper left deltoid of the arm.
Study NCT02679222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coconut oil
Description: 20 g of coconut oil
Study NCT02679222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coconut oil + MCT
Description: 10 g of coconut oil + 10 g of MCT (60 of C8 + 40 of C10)
Study NCT02679222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MCT
Description: 20 g of MCT (60 of C8+40 of C10)
Study NCT02679222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Coconut oil + tricaprylin
Description: 10 g coconut oil + 10 g tricaprylin
Study NCT02679222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tricaprylin
Description: 20 g tricaprylin
Study NCT02679222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Tricaprin
Description: 20 g tricaprin
Study NCT02679222 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Control
Description: No supplement taken on this visit
Study NCT03238209 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Exercise testing
Description: The test consisted of a steady-state resting period of 3 min followed by 1 min of unloaded pedaling at 60 cycles/min for each individual; the exercise load was increased by 10 W each min until the test had to be stopped because symptoms prevented further exercise. After test results were recorded, EMGdi,es and each surface inspiratory EMG of maximal exercise capacity were analysed.
Study NCT02827084 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Kinesio Taping
Description: Application of the Kinesio Taping with tension in the vatus mediallis muscle.
Study NCT02827084 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Application of the Kinesio Taping without tension in the vatus mediallis muscle.
Study NCT03112343 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Algorithm-based feedback messages
Description: ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention
Study NCT03112343 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Personal Health Record
Description: Subjects will save and send their health information to the server via the personal health record app
Study NCT03112343 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Personal Health Record
Description: Subjects will save and send their health information to the server via the personal health record app
Study NCT02487576 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Carbohydrate-rich (HC)
Description: 65% Carbohydrate; 20% Fat; 15% Protein
Study NCT02997748 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning (RIPC)
Description: 3 cycles or more cycles of 5 to 10-min inflation of a blood-pressure cuff to 200 mm HG (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed in arm 6.
Study NCT02997748 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Remote ischemic preconditioning (RIPC)
Description: 3 cycles or more cycles of 5 to 10-min inflation of a blood-pressure cuff to 200 mm HG (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed in arm 6.
Study NCT02565511 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAD106 Immunotherapy
Description: Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
Study NCT02565511 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to CAD106
Description: Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
Study NCT02565511 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNP520
Description: CNP520 50 mg capsule p.o. for the duration of the Treatment Epoch.
Study NCT02487576 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fat-rich (HF)
Description: 35% Carbohydrate; 50% Fat; 15% Protein
Study NCT02565511 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to CNP520
Description: Placebo to CNP520 p.o. for the duration of the Treatment Epoch
Study NCT02565511 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Alum
Description: Alum was mixed with reconstituted CAD106 as adjuvant therapy to maximize the effectiveness of CAD106
Study NCT02565511 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alum
Description: Alum was mixed with reconstituted CAD106 as adjuvant therapy to maximize the effectiveness of CAD106
Study NCT01691235 — intervention group
Intervention type: DEVICE
Intervention: SIMpill device
Description: The SIMpill device is an automated pill dispensing device that records a time stamp each time the device is opened and a dose of medication is taken. This works through a computer chip that is housed inside of the pill dispensing device that is activated each time the pill box is opened. Physicians can download this data and generate a precise account of the patient's adherence to the medication dosing schedule. In addition, if a dose is missed, the SIMpill device can be set to automatically notify the patient by text message if a dose is overdue.
Study NCT01572805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melatonin 3mg
Description: To receive sublingual 3 mg melatonin before spinal of anesthesia .
Study NCT01572805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: melatonin 6mg
Description: To receive sublingual 6 mg melatonin before spinal of anesthesia .
Study NCT01572805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: To receive sublingual placebo tablet before spinal of anesthesia .
Study NCT03015220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Oral administration once-daily, as add-on to pre-trial oral antidiabetic drug (OAD).
Study NCT03015220 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dulaglutide
Description: Subcutaneously administration (s.c., under the skin) once-weekly, as add-on to pre-trial oral antidiabetic drug (OAD).
Study NCT02084615 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: Subjects will undergo open inguinal hernia repairs while taking their normal dose of 81mg, 325mg, or no aspirin
Study NCT01673256 — intervention group
Intervention type: DEVICE
Intervention: SJM Confirm ICM
Study NCT03854565 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Glycocalyx measurement，respiratory mechanics measurement
Description: ELASA measure glycocalyx, measure plateau pressure, driving pressure
Study NCT02280382 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Femmeze®
Description: Femmeze will be used by women in the intervention group for 8 weeks These women will be measuring against their usual care in a linear design; measurement will include validated questionnaires
Study NCT01262040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Narrow Band Imaging (NBI)
Description: The intervention is visual assessment of the peritoneal or pleural surface with NBI followed by biopsy and photographic documentation of any abnormal lesions. Photograph or video of abnormality(ies) under white light and NBI.
Study NCT01238757 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-invasive Ventilation under Pressure Support
Description: Non-invasive Ventilation under Pressure Support:~15 min with initial settings, 5 min with ETS-%%, 5 min with ETS+10%, in random order
Study NCT01238757 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-Invasive ventilation under NAVA
Description: 20 min session under non-invasive ventilation with NAVA
Study NCT01778140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient-specific computerized reminder
Description: The intervention targets are physicians,not patients. This CDSS alerts physicians only when the patient with high risk of contrast-induced-nephropathy(CIN) is encountered. On the contrast, the CDSS will not alert when the patient without CIN risk is encountered.
Study NCT01778140 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Non-patient-specific computerized reminder
Description: The non-patient-specific computerized reminder always pops up to remind physicians to check their patient's CIN risk no matter what CIN risk is.
Study NCT01434927 — intervention group
Intervention type: PROCEDURE
Intervention: Unsedated colonoscopy
Description: Patients were offered to undergo colonoscopy without routine premedication
Study NCT01434927 — intervention group
Intervention type: PROCEDURE
Intervention: Unsedated colonoscopy
Description: Patients were offered to undergo unsedated procedure. Their demographics and clinical data were recorded
Study NCT03124329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronally Advanced Flap
Description: Coronally advanced flap will be performed. Briefly, sulcular incisions will be made. Oblique incisions will be made on each papilla requiring root coverage. In the region coronal to the mucogingival junction (MGJ), mucoperiosteal flap will be elevated. Apical to the MGJ, sharp dissection will be performed to the periosteum allowing split-thickness flap elevation to be performed. Epithelium is removed from the papillae adjacent to the recession and the flap is coronally positioned and stabilized with interproximal sutures and apico-coronal interrupted sutures to close the vertical releasing incisions.
Study NCT03124329 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intrasulcular Tunneling
Description: Initial sulcular incisions are made and small, contoured blades and mini curettes are used to create the recipient pouches and tunnels. The tunnel will be subperiosteal in location. The incision is extended to one adjacent tooth both mesially and distally. This incision maintains the full height and thickness of the gingival component and enables access beneath the buccal gingiva. The connective tissue beyond the mucogingival line will be dissected and free the buccal flap from its insertions to the bone around each tooth. Muscle fibers and any remaining collagen fibers on the inner aspect of the flap, which prevent the buccal gingiva from being moved coronally, are cut. The papillae are kept intact and undermined to maintain their integrity and carefully released from the underlying bone, which allows the coronal positioning of the papillae. An envelope, full-thickness pouch, and tunnel are created and extended apically beyond the mucogingival line by blunt dissection
Study NCT03124329 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Vestibular Incision Subperiosteal Tunnel Access (VISTA)
Description: The VISTA approach begins with a Vestibular Incision Subperiosteal Tunnel Access. Through this incision a subperiosteal tunnel is created, exposing the facial osseous plate and root dehiscence. This tunnel will be extended at least one or two teeth beyond the teeth requiring root coverage to mobilize gingival margins and facilitate coronal repositioning. Additionally, the subperiosteal tunnel is extended interproximally under each papilla as far as the embrasure space permits, without making any surface incisions through the papilla. The mucogingival complex is then advanced coronally and stabilized in the new position with the coronally anchored suturing technique, which entails placing a horizontal mattress suture apical to the gingival margin of each tooth. The suture is tied to position the knot at the midcoronal point of the facial aspect of each tooth, which is secured with help of composite resin to prevent apical relapse of the gingival margin during initial stages of healing.
Study NCT03124329 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Leukocyte-Platelet Rich Fibrin (L-PRF)
Description: Immediately prior to surgery, 72 mL of blood should be drawn from each patient by venipuncture of the antecubital vein and collected in a sterile glass test tube without any anticoagulant. Tubes should be centrifuged at 2,700 rpm for 12 minutes within 2 minutes after blood draw. For individuals on anti-coagulant therapy or supplements to interfere with coagulation, centrifugation will be for 18 minute. After centrifugation, each L-PRF clot will be separated from the portion of red blood cells (red thrombus), obtaining a fibrin clot with a red small portion in order to include the buffy coat richer in leucocytes. The L-PRF clot is condensed and modeled on a sterile surgical plate. L-PRF will be used within 60 minutes after the preparation.
Study NCT02636049 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triferic
Description: Triferic is supplied as sterile 5 mL ampules containing 5.44 mg/mL of iron in water for injection. Each 5 mL ampule contains 27.2 mg of Triferic iron.
Study NCT02367196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-90002
Study NCT02367196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT04907942 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMA + Automated Text Message Intervention
Description: Intervention includes 3 weeks of EMA (2 daily surveys per day delivered during waking hours to evaluate momentary affects) plus 2 weeks of automated text messages delivered twice a day, which content follows constructs from The Transactional Model of Stress and Coping.
Study NCT04907942 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: EMA Alone
Description: Three weeks of EMA consisting of 2 daily surveys per day delivered during waking hours to evaluate momentary affects.
Study NCT04613076 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Me cuido y me siento mejor
Description: A multicomponent, collaborative, computer-assisted, psycho-educational intervention for the management of depressive symptoms in primary care patients with diabetes and/or hypertension.
Study NCT04613076 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Treatment
Description: Enhanced Usual Treatment
Study NCT00052494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Study NCT00052494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Study NCT00052494 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Study NCT03525613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: APL-2
Description: Complement (C3) Inhibitor
Study NCT03525613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: Subjects will receive a Sham procedure every month
Study NCT03525613 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sham Procedure
Description: Subjects will receive a Sham procedure every other month
Study NCT01317368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naropine
Description: 20 mL of 0,75% Naropin is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL of saline 0,9% will be deposited subcutaneously as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once.
Study NCT01317368 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naropine
Description: 20 mL Saline 0,9% is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL Ropivacaine 0,75% will be deposited subcutaneously as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once.
Study NCT01317368 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 20 mL 0,9% Saline is deposited on each side (40 mL in total) in the TAP.~At the same time 40 mL Saline 0,9% will be given as wound infiltration.~Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once.
Study NCT03925493 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Graded Exercise Stress test (GXT) with Target Heart Rate Range
Description: Patients assigned to one of two intervention groups will complete a GXT prior to the 4th CR session. The GXT will be completed in Baystate Medical Center's stress lab using standard protocols. This test will be used to set the target heart rate range, which will guide exercise intensity for the remainder of exercise training in cardiac rehabilitation.